SCHEMBL3496243

SCHEMBL3496243

CN1C(C)(C)CC(Nc2nc(Nc3ccc(-n4cccc4)c(C#N)c3)ncc2F)CC1(C)C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.49
CSNK2A2 P19784 4/20 0.43
CSNK2A1 P68400 4/20 0.43
SYK P43405 4/20 0.41
CSF1R P07333 2/20 0.39
CDK4 P11802 1/20 0.39
CDK6 Q00534 1/20 0.39
EGFR P00533 4/20 0.38
BTK Q06187 3/20 0.38
KDR P35968 2/20 0.38
ITK Q08881 2/20 0.38
AURKA O14965 2/20 0.38
PAK1 Q13153 2/20 0.38
CDK2 P24941 2/20 0.38
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
CHEK1 O14757 1/20 0.38
DCLK1 O15075 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3495587 0.92 SYK (0.41) PRKCQCSNK2A2CSNK2A1SYKAURKA
SCHEMBL3496178 0.90 PAK1 (0.45) PRKCQCSNK2A2CSNK2A1PAK1JAK2
SCHEMBL3496481 0.89 ULK1 (0.46) CDK6AURKAPAK1CDK2CHEK1
SCHEMBL3495489 0.89 PRKCQ (0.50) PRKCQCSNK2A2CSNK2A1SYKCSF1R
SCHEMBL3497992 0.89 PRKCQ (0.54) PRKCQCSNK2A2CSNK2A1SYKEGFR
SCHEMBL3496000 0.89 PRKCQ (0.54) PRKCQCSNK2A2CSNK2A1SYKEGFR
SCHEMBL3497842 0.88 KDR (0.50) PRKCQCSNK2A2CSNK2A1SYKCSF1R
SCHEMBL3496812 0.87 PRKCQ (0.55) PRKCQCSNK2A2CSNK2A1SYKCSF1R
SCHEMBL3495391 0.86 PRKCQ (0.52) PRKCQCSNK2A2CSNK2A1SYKEGFR
SCHEMBL3494941 0.85 PRKCQ (0.56) PRKCQSYKEGFRBTKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885CSNK2A2 643/4885CSNK2A1 617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.